All In Biotech

Drug Trial Radar · NCT07128381

Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

66

Planned (sponsor's estimate)

Start

Jan 2, 2026

Primary completion

Jul 31, 2031

Study completion Jul 31, 2033

Sponsor

Lead sponsor
M.D. Anderson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Incyte, Inc
First posted
Aug 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

* To find the recommended dose of axatilimab given alone and in combination with ruxolitinib in patients with MF and CMML. * To learn if axatilimab given in combination with ruxolitinib can help to control MF and CMML.

Conditions

  • Myelofibrosis (MF)
  • Chronic Myelomonocytic Leukemia (CMML)

Interventions

  • Axatilimab (SNDX-6352)Drug

    Taken orally

  • RuxolitinibDrug

    Taken orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Adverse Events (AEs)Time frame: Through study completion; an average of 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The University of Texas M. D. Anderson Cancer Center

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.